-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexaria Completes Dosing in Five-Week Oral Semaglutide Study

PUBT·11/19/2026 14:01:08
Listen to the news
Lexaria Completes Dosing in Five-Week Oral Semaglutide Study
  • Lexaria Bioscience announced November 19, 2026, that dosing finished on schedule in its five-week human study GLP-1-H26-7.
  • The trial compares DehydraTECH-semaglutide tablets and capsules with Novo's commercial Wegovy tablets, assessing safety, tolerability and drug absorption.
  • This marks the first human trial of its DehydraTECH-semaglutide tablet formulation, extending testing beyond capsules.
  • Results will be reported following laboratory analysis, data review and quality checks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611190900ACCESSWRNAPR_____1253854) on November 19, 2026, and is solely responsible for the information contained therein.